Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Marketing authorisation indication

Atezolizumab (Tecentriq, Roche) has a marketing authorisation for 'the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy or who are considered cisplatin ineligible'.

Dosage in the marketing authorisation

1,200 mg by intravenous infusion every 3 weeks.

Price

A 1,200 mg vial costs £3,807.69 excluding VAT (company submission).

The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.